Patheon halts Omnicef manufacturing
Patheon subsidiary CEPH voluntarily suspends production of Abbott's Omnicef (cefdinir) powder for oral suspension at its Puerto Rico manufacturing facility after receiving a warning letter from FDA, company says Sept. 28. The CEPH facility was cited by FDA for "out of specification results" due to fill weight variations, failure to implement corrective actions to assure unit product quality, and failure to act on post-marketing adverse event reports that "stated lack of effectiveness." Abbott and Patheon have sent teams to the facility to ensure that corrective measures are implemented. Patheon is Abbott's only Omnicef supplier, but Abbott says it will be able to supply the oral suspension antibiotic to patients requiring it. Production of Omnicef 300 mg capsules remains unaffected...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.